Διοργάνωση:

- Εταιρεία Ογκοπόγων Παθοπόγων Εππάδαs
- Ελληνική Εταιρεία
 Ακτινοθεραπευτικής Ογκολογίας

Σε συνεργασία με:

- Επληνική Εταιρεία Χειρουργικής Ογκολογίας
- Εθνικό Σύνδεσμο Νοσηλευτών Ελλάδοs Τομέα Νοσηλευτικής Ογκολογίας







ακτινοθεραπεία πρώιμου καρκίνου μαστού: νεότερα δεδομένα

Ιωάννης Γεωργακόπουλος Ακτινοθεραπευτής Ογκολόγος


δήλωση συμφερόντων

δηλώνω ότι δεν έχω (προσωπικά ή ως μέλος εργασιακής/ερευνητικής ομάδας) ή μέλος της οικογένειάς μου οποιοδήποτε οικονομικό ή άλλου είδους όφελος από τις εταιρείες/επιχειρήσεις που διοργανώνουν/χρηματοδοτούν την άνω εκδήλωση κατά τη διάρκεια των τελευταίων 4 ετών

outline

- general facts
- the evidence
 - RT: DCIS, BCT & mastectomy
 - Regional Nodal Irradiation (RNI)
- emerging data
- new treatment options of breast radiotherapy
 - hypofractionation
 - Accelerated Partial Breast Irradiation (APBI)
 - techniques of EBRT: Intensity Modulated Radiation Therapy (IMRT)
- predictive biomarkers in RT

SEER data



Cancer Statistics 2016

Leading Sites of New Cancer Cases and Deaths – 2016 Estimates

Estimated New Cases		Estimated Deaths	
Male	Female	Male	Female
Prostate	Breast	Lung & bronchus	Lung & bronchus
180,890 (21%)	246,660 (29%)	85,920 (27%)	72,160 (26%)
Lung & bronchus	Lung & bronchus	Prostate	Breast
117,920 (14%)	106,470 (13%)	26,120 (8%)	40,450 (14%)
Colon & rectum	Colon & rectum	Colon & rectum	Colon & rectum
70,820 (8%)	63,670 (8%)	26,020 (8%)	23,170 (8%)
Urinary bladder	Uterine corpus	Pancreas	Pancreas
58,950 (7%)	60,050 (7%)	21,450 (7%)	20,330 (7%)
Melanoma of the skin	Thyroid	Liver & intrahepatic bile duct	Ovary
46,870 (6%)	49,350 (6%)	18,280 (6%)	14,240 (5%)
Non-Hodgkin lymphoma	Non-Hodgkin lymphoma	Leukemia	Uterine corpus
40,170 (5%)	32,410 (4%)	14,130 (4%)	10,470 (4%)
Kidney & renal pelvis	Melanoma of the skin	Esophagus	Leukemia
39,650 (5%)	29,510 (3%)	12,720 (4%)	10,270 (4%)
Oral cavity & pharynx	Leukemia	Urinary bladder	Liver & intrahepatic bile duct
34,780 (4%)	26,050 (3%)	11,820 (4%)	8,890 (3%)
Leukemia	Pancreas	Non-Hodgkin lymphoma	Non-Hodgkin lymphoma
34,090 (4%)	25,400 (3%)	11,520 (4%)	8,630 (3%)
Liver & intrahepatic bile duct 28,410 (3%)	Kidney & renal pelvis 23,050 (3%)	Brain & other nervous system 9,440 (3%)	Brain & other nervous system 6,610 (2%)
All sites	All sites	All sites	All sites
841,390 (100%)	843,820 (100%)	314,290 (100%)	281,400 (100%)

Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder.


@2016, American Cancer Society, Inc., Surveillance Research

sentinel lymph node biopsy (SLNB)

- evaluation of nodes became "easier", less morbidity to patients and less extensive surgery
- false negative rate is similar to ALND (2-12%), likely not increased with neoadjuvant ChT

Buchholz et al. 2008

very low rate of subsequent axillary recurrence (<5%)



the evidence

- role of RT in DCIS, BCT & mastectomy
- Regional Nodal Irradiation (RNI)

RT & DCIS EBCTCG meta analysis

JNCI MONOGRAPHS


Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

J Natl Cancer Inst Monogr 2010;41:162–177

- 4 randomized trials
- 3729 pts

RT & DCIS EBCTCG meta analysis



RT & DCIS conclusions EBCTCG meta analysis

- 50% benefit across the randomized trials
- RT reduced the absolute 10-year risk of any ipsilateral breast event by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 *P* < .00001)
- effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, margin status, focality, grade, comedonecrosis, architecture, or tumor size

RT & BCT EBCTCG meta analysis

Articles


Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials



Early Breast Cancer Trialists' Collaborative Group (EBCTCG)*
Lancet 2011; 378: 1707-16

- 17 randomized trials
- 10801 pts

RT & BCT EBCTCG meta analysis



RT & BCT conclusions EBCTCG meta analysis

- reduced the 10-year risk of any (ie, locoregional or distant) first recurrence from 35.0% to 19.3% (absolute reduction 15.7%, 95% CI 13.7–17.7, p<0.00001)
- reduced the 15-year risk of breast cancer death from 25.2% to 21.4% (absolute reduction 3.8%, 1.6–6.0, p=0.00005)
- RT to the conserved breast, halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth

RT & mastectomy EBCTCG meta analysis

Articles

Effect of radiotherapy after mastectomy and axillary surgery $\Rightarrow @ \uparrow \bullet \bigcirc$ on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials






EBCTCG (Early Breast Cancer Trialists' Collaborative Group)* Lancet 2014; 383: 2127-35

- 22 randomized trials
- 8135 pts

RT & mastectomy EBCTCG meta analysis



Effect of radiotherapy (RT) after mastectomy and axillary dissection (Mast+AD) on 10-year risks of locoregional and overall recurrence and on 20-year risk of breast cancer mortality in 1772 women with four or more pathologically positive nodes (pN4+)

take home message

- RT beneficial in early breast cancer treatment management
- meta analysis data suggest benefit from RNI
- the beneficial effect of radiotherapy is offset by heart & lung toxicity
- new treatment options to optimize therapeutic effect
- several promising biomarkers on the horizon but require further clinical assessment



σας ευχαριστώ!